We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a ...

Fintel reports that on February 24, 2025, Wells Fargo downgraded their outlook for Exelixis (NasdaqGS:EXEL) from Overweight ...

Wells Fargo downgraded Exelixis (EXEL) to Equal Weight from Overweight with an unchanged price target of $36.Discover the Best Stocks and ...

Wells Fargo downgraded Exelixis (EXEL) to Equal Weight from Overweight with an unchanged price target of $36. While there is a better chance ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the ...

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...

Like its predecessor, this one is capped at $500 million. After market close on Thursday, Exelixis announced that it will launch a new share repurchase program, authorized for up to $500 million ...

On Friday, Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans to complete the $500 ...